Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2017-01-17 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. It includes a press release as Exhibit 99.1 dated January 17, 2017. The text indicates this is a report pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, which is typically used by foreign private issuers to furnish reports that are not annual or quarterly reports. The document length is only 2670 characters, and it mainly references the attached press release rather than containing substantive financial data or detailed report content. According to the 'Menu vs Meal' rule, such a short document that states a report or press release is attached and incorporated by reference should be classified as a Regulatory Filing (RNS) rather than the report itself. Therefore, this filing is best classified as a Regulatory Filing (RNS).
2017-01-17 English
SAPHIRA 1 topline shows competitive clinical results in G551D patients
Earnings Release Classification · 95% confidence The document is a press release dated December 20, 2016, announcing 'topline results' from the SAPHIRA 1 Phase 2 study for a drug candidate (GLPG1837) in cystic fibrosis patients. It details clinical outcomes (sweat chloride decrease, FEV1 levels) and mentions an upcoming conference call/webcast to discuss these results. This format—a concise announcement of key periodic financial/clinical results, often preceding a more detailed presentation or call—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational news. Since it focuses purely on clinical trial results and not comprehensive quarterly financials (which would suggest IR or 10-K), and it is an initial announcement of results, 'Earnings Release' (ER) is the most appropriate classification, even though the content is clinical rather than purely financial earnings. It is not a full transcript (CT), a full annual report (10-K), or just a notice of a report publication (RPA), as it contains the actual results summary. FY 2016
2016-12-21 English
SAPHIRA 1 topline shows competitive clinical results in G551D patients
Earnings Release Classification · 95% confidence The document is a press release dated December 20, 2016, announcing the results of the SAPHIRA 1 Phase 2 study for the drug GLPG1837 in cystic fibrosis patients. It details clinical outcomes (reduction in sweat chloride levels, safety profile) and includes quotes from researchers and management. Crucially, it announces an upcoming webcast presentation for investors regarding these results. This structure—announcing key results and immediately scheduling a call/webcast for detailed discussion—is characteristic of an Earnings Release (ER) or a general announcement of significant news. Since the content is focused on clinical trial results rather than quarterly financial performance metrics (which would suggest an ER or IR), and it is a formal announcement of new data, it fits best as an Earnings Release (ER) if we interpret 'Earnings' broadly as 'Results Announcement', or potentially an Investor Presentation (IP) if the webcast is the main event. However, the text itself is the announcement of the results, not the presentation slides. Given the focus on announcing key data points and the immediate scheduling of a call to discuss them, it strongly aligns with the function of an Earnings Release (ER) which is the 'Initial announcement of periodical financial results (key highlights only)'. Although this is clinical data, in the biotech/pharma context, major trial results often substitute for or accompany quarterly earnings announcements as the primary news driver. Since it is a formal press release announcing key data highlights and scheduling a follow-up call, ER is the most appropriate fit among the options for a time-sensitive results announcement. Q4 2016
2016-12-21 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of December 2016. It includes a press release as Exhibit 99.1 but does not contain any substantive financial data or detailed report content itself. The document is relatively short (2671 characters) and primarily serves to furnish a report or document required by the issuer's home country regulations. It references incorporation into registration statements but does not present financial statements or detailed analysis. According to the rules, such filings that provide a report or document without substantive financial data and are short in length are classified as Regulatory Filings (RNS).
2016-12-21 English
SAPHIRA 1 toont competitieve klinische resultaten in G551D patiënten
Earnings Release Classification · 95% confidence The document is dated '20 december 2016' and is titled as 'Gereglementeerde informatie' (Regulated information). It announces clinical results for a drug candidate (GLPG1837) from a Phase 2 study (SAPHIRA 1) and includes quotes from management and researchers. Crucially, it announces a subsequent 'Webcast presentatie' (Webcast presentation) for the following day to discuss these results, including dial-in details. This structure—announcing key results and immediately scheduling a call to discuss them in detail—is characteristic of an Earnings Release (ER) or a similar primary results announcement. Since it focuses on clinical trial results rather than quarterly financial performance metrics (like revenue, EPS), and it is a formal announcement of new data, it aligns best with the function of an Earnings Release (ER) or a major clinical data disclosure, which often falls under the ER category when it's the initial public release of performance/study data. It is not a full Annual Report (10-K), a transcript (CT), or just a notice of a report publication (RPA). Given the context of clinical trial results being released to the market, ER is the most appropriate fit among the provided options for a primary performance/data disclosure. FY 2016
2016-12-20 Dutch
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Galapagos NV, pursuant to SEC rules. It references a press release attached as Exhibit 99.1 dated December 15, 2016. The document length is only 2567 characters, which is quite short and primarily serves to submit the press release. There is no substantive financial data or detailed report content within this filing itself. According to the 'Menu vs Meal' rule, such short filings that attach or reference another report or press release are classified as Regulatory Filings (RNS), not as the report itself. Therefore, this document is best classified as a Regulatory Filing (RNS).
2016-12-19 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.